Guardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of “Moderate Buy” by Brokerages

Guardant Health, Inc. (NASDAQ:GH) has earned an average recommendation of “Moderate Buy” from the twenty-four analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty-two have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $107.4545.

GH has been the topic of several analyst reports. Morgan Stanley lifted their target price on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Citigroup raised their price objective on Guardant Health from $100.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. UBS Group reaffirmed a “buy” rating and issued a $175.00 price target on shares of Guardant Health in a report on Friday, January 30th. Mizuho set a $135.00 price objective on Guardant Health in a research note on Friday, January 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, January 22nd.

Insider Activity at Guardant Health

In other news, CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the completion of the sale, the chief executive officer directly owned 2,047,143 shares of the company’s stock, valued at $212,534,386.26. The trade was a 4.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Chris Freeman sold 31,452 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $103.07, for a total value of $3,241,757.64. Following the completion of the transaction, the insider owned 25,987 shares in the company, valued at approximately $2,678,480.09. This trade represents a 54.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 434,511 shares of company stock valued at $45,580,887 over the last 90 days. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new stake in Guardant Health during the 4th quarter valued at approximately $27,000. Chesapeake Asset Management LLC purchased a new position in shares of Guardant Health during the 4th quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health during the fourth quarter worth approximately $31,000. IFP Advisors Inc grew its position in shares of Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after buying an additional 334 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new stake in shares of Guardant Health in the fourth quarter worth $35,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Trading Up 0.3%

Shares of GH opened at $107.42 on Friday. Guardant Health has a 12-month low of $34.88 and a 12-month high of $120.74. The firm has a market cap of $13.54 billion, a PE ratio of -33.46 and a beta of 1.63. The company’s 50 day simple moving average is $106.57 and its 200-day simple moving average is $85.39.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.